{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:09:31Z","timestamp":1754111371809,"version":"3.37.3"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010154","name":"Fundaci\u00f3n P\u00fablica Andaluza para la Gesti\u00f3n de la Investigaci\u00f3n en Salud de Sevilla","doi-asserted-by":"publisher","award":["AP-0222-2019"],"award-info":[{"award-number":["AP-0222-2019"]}],"id":[{"id":"10.13039\/100010154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01281"],"award-info":[{"award-number":["PI20\/01281"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Oral anticoagulants (OACs) are first-line drugs for stroke prevention in patients with atrial fibrillation (AF). The introduction of new lines of therapy with direct oral anticoagulants (DOACs) has led to a decreased use of vitamin K antagonists (VKAs). Comparative analyses of DOACs in clinical trials are scarce and the comparator has mostly been warfarin. Their impact on health outcomes in observational studies has not always been consistent. The aim of this study is to evaluate the effectiveness and safety of DOACs and VKAs in patients with AF using Real-World Data (RWD).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and analysis<\/jats:title>\n<jats:p>Population-based retrospective cohort study using RWD from actual practice. Period: January 2012-December 2020. Inclusion criteria: patients with AF who had not taken OACs in the previous 12 months. Exclusion criteria: &lt;40 years, with severe mitral stenosis, or valvular heart disease or aortic and\/or mitral valve procedures. Data source: The Andalusian Population Health Database, Spain. Outcome measures: a) Effectiveness: ischaemic stroke, transient ischaemic attack, systemic and pulmonary embolism, and death; b) Safety: gastrointestinal and intracranial haemorrhaging; Independent variables: age, sex, comorbidities, medication and health resource use, CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VAS<jats:sub>C<\/jats:sub>, HAS-BLED, and analytical tests. Statistical analysis: crude incidence analysis, survival models, Kaplan-Meier, Cox regression analysis adjusted for possible confounding and paired analysis by propensity score matching.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0294822","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T18:36:00Z","timestamp":1701282960000},"page":"e0294822","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and safety of oral anticoagulant therapy in a real-world cohort with atrial fibrillation: The SIESTA-A study protocol"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3135-777X","authenticated-orcid":true,"given":"M. C.","family":"Montero-Balosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Lim\u00f3n-Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Leal-Atienza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. G.","family":"Luque-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Aguado-Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Isabel-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Molina-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"pone.0294822.ref001","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.STR.27.10.1765","article-title":"Acute stroke with atrial fibrillation. The Copenhagen Stroke Study","volume":"27","author":"HS J\u00f8rgensen","year":"1996","journal-title":"Stroke"},{"key":"pone.0294822.ref002","first-page":"760","article-title":"Stroke severity in atrial fibrillation. The Framingham Study","volume":"27","author":"HJ Lin","year":"1996","journal-title":"Stroke"},{"key":"pone.0294822.ref003","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1161\/CIRCULATIONAHA.112.105908","article-title":"Guided antithrombotic therapy: current status and future research direction: report on a national heart, lung and blood institute working group","volume":"126","author":"V Fuster","year":"2012","journal-title":"Circulation"},{"key":"pone.0294822.ref004","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.hrthm.2019.01.024","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"16","author":"CT January","year":"2019","journal-title":"Heart Rhythm"},{"key":"pone.0294822.ref005","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"pone.0294822.ref006","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in non valvular atrial fibrillation","volume":"365","author":"MR Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0294822.ref007","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0294822.ref008","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"RP Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"pone.0294822.ref009","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.112.115410","article-title":"Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature","volume":"126","author":"F Dentali","year":"2012","journal-title":"Circulation"},{"key":"pone.0294822.ref010","doi-asserted-by":"crossref","first-page":"j510","DOI":"10.1136\/bmj.j510","article-title":"Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"356","author":"P Nielsen","year":"2017","journal-title":"BMJ"},{"issue":"8","key":"pone.0294822.ref011","doi-asserted-by":"crossref","first-page":"e2120064","DOI":"10.1001\/jamanetworkopen.2021.20064","article-title":"Oral Anticoagulants for non valvular atrial fibrillation in patients with high risk of gastrointestinal bleeding","volume":"4","author":"GY Lip","year":"2021","journal-title":"JAMA Netw Open"},{"key":"pone.0294822.ref012","doi-asserted-by":"crossref","first-page":"e0218878","DOI":"10.1371\/journal.pone.0218878","article-title":"Association of stroke and bleed events in non-valvular atrial fibrillation patients with direct oral anticoagulant prescriptions in NHS England between 2013 and 2016.","volume":"14","author":"H Sheth","year":"2019","journal-title":"PLoS ONE."},{"key":"pone.0294822.ref013","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1111\/bcp.14669","article-title":"Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis","volume":"87","author":"M Durand","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0294822.ref014","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.7326\/M21-1474","article-title":"Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants. A nationwide propensity score\u2013weighted study","volume":"174","author":"AB Ingason","year":"2021","journal-title":"Ann Intern Med"},{"key":"pone.0294822.ref015","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/bcp.14430","article-title":"Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population-based propensity-weighted cohort study","volume":"87","author":"CL Rodr\u00edguez-Bernal","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0294822.ref016","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.3390\/ijerph18115700","article-title":"Anticoagulation control with acenocoumarol or warfarin in non-valvular atrial fibrillation in primary care (Fantas-TIC Study).","volume":"18","author":"MR Dalmau","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"pone.0294822.ref017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.gaceta.2019.03.003","article-title":"Conexi\u00f3n de registros sanitarios: base poblacional de salud de Andaluc\u00eda.","volume":"34","author":"D Mu\u00f1oyerro-Mu\u00f1iz","year":"2020","journal-title":"Gac Sanit."},{"key":"pone.0294822.ref018","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-1353-0","volume-title":"Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models","author":"E Vittinghoff","year":"2012","edition":"2"},{"key":"pone.0294822.ref019","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"E von Elm","year":"2007","journal-title":"The Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T18:36:25Z","timestamp":1701282985000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294822"}},"subtitle":[],"editor":[{"given":"Xinlin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0294822","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,11,29]]}}}